Drug Database
Back to search

Poland· PL-100363024

Spectrila

A asparaginase product containing asparaginasum, registered in Poland by medac Gesellschaft fuer klinische Spezialpraeparate mbH. The same ATC class is registered in 15 of our 19 countries.

ATC L01XX02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedSpectrilaATCL01XX02REGISTER NO.PL-100363024PACKS LISTED3CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about asparaginasumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Asparaginase is registered in 15 of 19 countries.

Countries holding a registration under ATC L01XX02 (asparaginase), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search asparaginase products by name

Asparaginase · ATC L01XX02

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Asparaginasum
Manufacturer
medac Gesellschaft fuer klinische Spezialpraeparate mbH
Country
Poland (PL)
ATC code
L01XX02
ATC class
Asparaginase
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    04037353019461
  • gtin
    04037353017863
  • gtin
    04037353021952

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

280 interactions on record for asparaginase.

Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check asparaginase against other medicinesHow interaction checks work

Asparaginase · interactions on record

280 records

  • 7 severe
  • 273 moderate

Most severe, free to view

  • ClotrimazoleA01AB18moderate
  • Chenodeoxycholic acidA05AA01moderate
  • PrednisoloneA07EA01moderate
  • HydrocortisoneA07EA02moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Asparaginase in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All asparaginase products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Enrylaze, Spectrila
  • Liechtenstein · Enrylaze, Spectrila
  • Norway · Enrylaze, Spectrila

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/08055ea3-3e02-4afb-849e-f9af597999a9
GET /v1/drugs/08055ea3-3e02-4afb-849e-f9af597999a9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania koncentratu roztworu do infuzji",
  "source": "urpl",
  "strength": "10000 j.",
  "packaging": "Rpz ¦ EU/1/15/1072/001 ¦ 113836\n1 fiol. 20 ml\n¦ UR/Z/4c/075/24 - 04037353019461 ¦ UR/Z/4c/065/22 - 04037353017863 ¦ UR/Z/4c/012/22 - 04037353017863 ¦ UR/Z/4c/048/23 - 04037353017863, 04037353019461 ¦ UR/Z/4c/024/22 - 04037353017863 ¦ UR/Z/4c/114/25 - 04037353019461, 04037353021952 ¦ UR/Z/4c/043/26 - 04037353021952\nRpz ¦ EU/1/15/1072/002 ¦ 113837\n5 fiol. 20 ml",
  "substance": "Asparaginasum 10000 j.",
  "common_name": "Asparaginasum",
  "pl_product_id": "100363024",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about asparaginase.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console